We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Chitinases and Transforming Growth Factor Beta (TGFB) in Human Asthma (AADCRC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01073410
Recruitment Status : Active, not recruiting
First Posted : February 23, 2010
Last Update Posted : July 19, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to find out the roles of two specific gene families (the chitinase gene family and the TGFB family). We hypothesize that chitinases and TGFb pathway genes will be differentially expressed in the airways of non-asthmatic subjects and subjects with asthma. We further hypothesize that genetic variants in CHIT1, AMCase, and TGFb pathway genes that show associations with asthma and related phenotypes will change the expression and/or function of the protein of these genes in the airway in several ways, including the transcript numbers for full length genes and splice variants and, for the chitinase genes, the levels of chitinase activity in airway secretions.

Condition or disease

Detailed Description:
This is a cross-sectional study in patients with asthma and healthy controls in which we will analyze how the expression or function of CHIT1, AMCase, and TGFb pathway genes in the asthmatic airway is affected by genetic variation in these genes. We propose detailed phenotyping of the asthmatic subjects and the healthy controls, including collection of induced sputum, exhaled air and detailed physiologic measures including measures of airflow, lung volumes, and methacholine responsiveness as well as collection of airway cells and tissues by bronchoscopy. We will determine the relative expression of CHIT1 and AMCase in specific lung compartments (large airways, small airways, epithelial cells, macrophages) and the effects of genetic variants in CHIT1 and AMCase on expression of splice variants and levels of chitinase activity in the airway. These human samples will also allow us to determine if any of the multiple TGFb pathway genes analyzed show differential expression in the lung in asthma.

Study Design

Study Type : Observational
Actual Enrollment : 23 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Chitinases and TGFB in Human Asthma
Study Start Date : February 2010
Primary Completion Date : February 2017
Estimated Study Completion Date : April 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
U.S. FDA Resources

Groups and Cohorts

Healthy, non-asthmatic controls
People who are non-asthmatic and non-smokers.
People who have been diagnosed with asthma.

Outcome Measures

Primary Outcome Measures :
  1. Expression of CHIT1, AMCase, and TGFb pathway genes in asthma [ Time Frame: Current ]

Biospecimen Retention:   Samples With DNA
sputum, blood, saliva, DNA, RNA, Plasma

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Community sample

Inclusion Criteria:

  • History of asthma
  • No use of oral or inhaled corticosteroids for the treatment of asthma in the past 6 weeks
  • Hyperreactivity to methacholine (PC20FEV1 Methacholine ≤ 8.0 mg/mL).
  • At least one of the following symptoms, beta agonist use, or FEV1 criteria:

    • Asthma symptoms on at least two days per week, or
    • Beta agonist use on at least two days per week, or
    • FEV1 < 85% predicted
  • Subjects must be non-smokers (patients who have never smoked or patients who have not smoked for 1 year and have a total pack-year smoking history < 10 packs).

Exclusion Criteria:

  • Cigarette smoking: Subjects must be non-smokers. Non smokers are defined as subjects who have never smoked or who have not smoked for 1 year and have a total pack-year smoking history < 10 packs.
  • Pregnant women
  • Subjects with a history of a medical disease which in the opinion of the investigator may put the subject at extra risk from study-related procedures or because the disease may influence the results of the study.
  • Healthy control subjects must have no history of asthma or allergic rhinitis
  • Upper respiratory tract infection in the 4 weeks prior to enrollment in the study
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01073410

United States, California
UCSF Airway Clinical Research Center
San Francisco, California, United States, 94143
Sponsors and Collaborators
University of California, San Francisco
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Prescott G Woodruff, MD, MPH University of California, San Francisco
More Information

Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT01073410     History of Changes
Other Study ID Numbers: 10-02173
U19AI077439 ( U.S. NIH Grant/Contract )
First Posted: February 23, 2010    Key Record Dates
Last Update Posted: July 19, 2017
Last Verified: July 2017

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases